Rapport Therapeutics, Inc. (RAPP) News
Follow Rapport Therapeutics, Inc. (RAPP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Rapport Therapeutics Reports $40.2 Million Q3 Loss and Pipeline Update
The company reported a $40.2 million net loss for the third quarter of 2026, versus $26.9 million a year earlier, as research and development spending increased. It ended September with $395.0 million in cash, cash equiv
EQUITY | Nov 04, 2026, 12:41 PM UTC
M
Rapport Therapeutics Reports Q3 2026 Financials and Business Update
Rapport Therapeutics reported positive topline results from a Phase 2 trial of RAP-219 in bipolar mania; the body also references initiation of two Phase 3 trials but is truncated.
EQUITY | Nov 04, 2026, 12:20 PM UTC
M
Rapport Closes Stock, Warrant and Convertible Note Offerings
Rapport Therapeutics also said underwriters fully exercised their options to purchase additional shares and notes, alongside a concurrent private placement.
EQUITY | Nov 02, 2026, 12:09 PM UTC
M
Rapport Therapeutics Prices Stock and Convertible Notes Offerings
Rapport Therapeutics said it priced separate stock and convertible notes offerings and a private placement.
EQUITY | Oct 28, 2026, 02:59 PM UTC
M
Rapport Therapeutics shares fall 22.4% premarket
Rapport Therapeutics shares are down 22.4% premarket amid stock and convertible bond sales.
EQUITY | Oct 28, 2026, 12:14 PM UTC
L
BUZZ-US STOCKS ON THE MOVE-Phillips 66, GE Vernova, Seagate
BUZZ-US STOCKS ON THE MOVE-Phillips 66, GE Vernova, Seagate Workspace search string for individual s
EQUITY | Oct 28, 2026, 11:44 AM UTC
L
Rapport Therapeutics shares plunge premarket on stock and convertible debt offering
Rapport Therapeutics shares plunged in premarket trading following a stock and convertible debt offering.
EQUITY | Oct 28, 2026, 10:47 AM UTC
M
Rapport Prices Stock, Warrant and Convertible Note Offerings
Rapport announced pricing of underwritten offerings of common stock, pre-funded warrants and convertible notes, alongside a concurrent private placement.
EQUITY | Oct 28, 2026, 10:07 AM UTC
M
Rapport Therapeutics Announces $200 Million Stock and $150 Million Convertible Note Offerings
Rapport Therapeutics also announced a private placement. Its shares fell 19% after hours to $22.19.
EQUITY | Oct 27, 2026, 10:18 PM UTC
M
Rapport Therapeutics Shares Plunge After Equity and Convertible Bond Offerings
Rapport Therapeutics shares plunged after the company launched offerings of shares and convertible bonds.
EQUITY | Oct 27, 2026, 09:23 PM UTC
M
Rapport Proposes Common Stock and Convertible Note Offerings
Rapport Therapeutics proposed public offerings of common stock and convertible notes, alongside a concurrent private placement.
EQUITY | Oct 27, 2026, 08:59 PM UTC
L
Rapport Therapeutics to participate in upcoming investor conferences
Rapport Therapeutics says it will participate in upcoming investor conferences, a clinical-stage biotech focused on small molecule precision medicines.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
RAPP - Rapport Therapeutics to Participate in Upcoming Investor Conferences
RAPP - Rapport Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:00 AM UTC
M
Rapport Therapeutics Reports Q2 Financials
Rapport Therapeutics releases Q2 financials
EQUITY | Aug 05, 2026, 11:01 AM UTC
M
RAPP: Leerink Initiates
Leerink Partners initiates coverage on Rapport Therapeutics with Outperform rating and $52 price target
EQUITY | Jun 24, 2026, 06:41 PM UTC
M
RAPP Initiated Outperform
RAPP initiated with an Outperform rating at Leerink with a price target of $52
EQUITY | Jun 24, 2026, 11:44 AM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with OUTPERFORM, BUY, and EQUAL WEIGHT ratings
EQUITY | Jun 24, 2026, 10:54 AM UTC